CoChat
Sign Up
Cited by 150Psychedelics and Drug StudiesTryptophan and brain disordersPharmacological Receptor Mechanisms and Effects

The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.

Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities

Open access
Szabo, Attila·2015·Frontiers in Immunology
DOI 10.3389/fimmu.2015.00358PMC PMC4500993
Open this paper in CoChat — free accountOpen PDF

Abstract

Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular proliferation, and cell survival via activating NF-κB and mitogen-activated protein kinases. Recently, several neurotransmitter receptors involved in the pharmacology of psychedelics, such as serotonin and sigma-1 receptors, have also been shown to play crucial roles in numerous immunological processes. This emerging field also offers promising treatment modalities in the therapy of various diseases including autoimmune and chronic inflammatory conditions, infections, and cancer. However, the scarcity of available review literature renders the topic unclear and obscure, mostly posing psychedelics as illicit drugs of abuse and not as physiologically relevant molecules or as possible agents of future pharmacotherapies. In this paper, the immunomodulatory potential of classical serotonergic psychedelics, including N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-iodoamphetamine, and 3,4-methylenedioxy-methamphetamine will be discussed from a perspective of molecular immunology and pharmacology. Special attention will be given to the functional interaction of serotonin and sigma-1 receptors and their cross-talk with toll-like and RIG-I-like pattern-recognition receptor-mediated signaling. Furthermore, novel approaches will be suggested feasible for the treatment of diseases with chronic inflammatory etiology and pathology, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, schizophrenia, depression, and Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2015.00358

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [97]Holister L Some general thoughts about endogenous psychotogens. In: Usdin E Hamburg DA Barchas JD, editors. Neuroregulators and Psychiatric Disorders. New York, NY: Oxford University Press (1977). p. 550– 6.

Cited by

Sorted by citations

See all 150

Related

See all

Metadata

Authors
Szabo, A.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2015-07-14
Volume
6
Pages
358-358
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2015.00358
PMC
PMC4500993
OpenAlex
W1522923028
Cited by
150
References
154
Citations by year
2026: 13 · 2025: 16 · 2024: 16 · 2023: 35 · 2022: 17 · 2021: 17 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 3 · 2016: 11
FWCI
1.06
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, cc-by)
Funders
  • European Commission (-2012-0001, A/2-11-1-2012-0001, TÁMOP‐4.2.4.A/2‐11/1‐2012‐0001, 4.2.4.A/2-11-1-2012-0001)
  • European Social Fund (A/2–11/1-2012-0001, TÁMOP 4.2.4, -2012-0001)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
Keywords
psychedelics, immunomodulation, serotonergic psychedelics, serotonin receptors, sigma-1 receptor, N,N-dimethyltryptamine, 5-MeO-DMT, LSD, MDMA, NF-κB signaling, MAPK signaling, pattern recognition receptors, Toll-like receptors, RIG-I-like receptors, autoimmune disease, chronic inflammation, atherosclerosis, rheumatoid arthritis, multiple sclerosis, schizophrenia, depression, Alzheimer's disease, cancer immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review